KR20090021215A - 암의 치료를 위한 화합물 및 조성물 - Google Patents

암의 치료를 위한 화합물 및 조성물 Download PDF

Info

Publication number
KR20090021215A
KR20090021215A KR1020097000459A KR20097000459A KR20090021215A KR 20090021215 A KR20090021215 A KR 20090021215A KR 1020097000459 A KR1020097000459 A KR 1020097000459A KR 20097000459 A KR20097000459 A KR 20097000459A KR 20090021215 A KR20090021215 A KR 20090021215A
Authority
KR
South Korea
Prior art keywords
composition
cancer
mammal
dosage
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097000459A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 씨. 아델만
마크 제이. 에반칙
아난타 수다카르
제프리 윌리암 자콥스
제프리 에이. 실버만
Original Assignee
선에시스 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090021215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 선에시스 파마슈티컬스 인코포레이티드 filed Critical 선에시스 파마슈티컬스 인코포레이티드
Publication of KR20090021215A publication Critical patent/KR20090021215A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097000459A 2006-06-12 2007-06-12 암의 치료를 위한 화합물 및 조성물 Ceased KR20090021215A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81283506P 2006-06-12 2006-06-12
US60/812,835 2006-06-12

Publications (1)

Publication Number Publication Date
KR20090021215A true KR20090021215A (ko) 2009-02-27

Family

ID=38832517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097000459A Ceased KR20090021215A (ko) 2006-06-12 2007-06-12 암의 치료를 위한 화합물 및 조성물

Country Status (11)

Country Link
US (4) US8124773B2 (enExample)
EP (2) EP2043645A2 (enExample)
JP (3) JP2009539994A (enExample)
KR (1) KR20090021215A (enExample)
CN (2) CN104027333B (enExample)
AU (1) AU2007258280B2 (enExample)
BR (1) BRPI0713637A2 (enExample)
CA (1) CA2654876A1 (enExample)
IL (2) IL195883A0 (enExample)
MX (1) MX2008015775A (enExample)
WO (1) WO2007146335A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5317472B2 (ja) 2004-03-15 2013-10-16 サネシス ファーマシューティカルズ， インコーポレイテッド Ｓｎｓ−５９５、及びその使用方法
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
AU2008317400B2 (en) 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
RU2548031C2 (ru) * 2008-12-31 2015-04-10 Санесис Фармасьютикалз, Инк. Способ получения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты
RU2558835C2 (ru) 2009-02-27 2015-08-10 Санесис Фармасьютикалз, Инк. Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
AU2013202641B2 (en) * 2009-09-04 2015-07-23 Sunesis Pharmaceuticals, Inc. Stable sns-595 compositions and methods of preparation
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5078966A (en) 1990-08-14 1992-01-07 Nalco Chemical Company Carbohydrazide to prevent hydrogen blistering and corrosion of metal surfaces in contact with refinery overhead condensates
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
PL181867B1 (pl) * 1994-06-14 2001-09-28 Dainippon Pharmaceutical Co Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
DE69813194T2 (de) 1997-01-13 2004-02-05 Kudos Pharmaceuticals Ltd. Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur-aktivität zu modulieren
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
JP2001523977A (ja) * 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
CA2363621A1 (en) * 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
WO2002036171A1 (en) * 2000-11-02 2002-05-10 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US20030016887A1 (en) * 2001-07-18 2003-01-23 Fu-Long Su Receiving bag with seal opening and sealing clip
WO2004085418A2 (en) 2003-03-24 2004-10-07 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
JP5317472B2 (ja) * 2004-03-15 2013-10-16 サネシス ファーマシューティカルズ， インコーポレイテッド Ｓｎｓ−５９５、及びその使用方法
US7387499B2 (en) 2004-08-13 2008-06-17 Gateway Inc. System and method for testing the operation of a cooling fan
KR20080041298A (ko) 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
HUE026693T2 (hu) * 2006-08-02 2016-07-28 Sunesis Pharmaceuticals Inc (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére
AU2008317400B2 (en) 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders

Also Published As

Publication number Publication date
JP2013209398A (ja) 2013-10-10
WO2007146335A2 (en) 2007-12-21
CA2654876A1 (en) 2007-12-21
US20100029708A1 (en) 2010-02-04
US20150150858A1 (en) 2015-06-04
US20120245198A1 (en) 2012-09-27
BRPI0713637A2 (pt) 2012-10-23
US8124773B2 (en) 2012-02-28
EP2043645A2 (en) 2009-04-08
AU2007258280B2 (en) 2013-05-02
IL195883A0 (en) 2009-09-01
US8765954B2 (en) 2014-07-01
CN104027333B (zh) 2017-05-17
US20170101404A1 (en) 2017-04-13
JP2009539994A (ja) 2009-11-19
CN104027333A (zh) 2014-09-10
CN101505753A (zh) 2009-08-12
AU2007258280A1 (en) 2007-12-21
IL243294A0 (en) 2016-02-29
WO2007146335A3 (en) 2009-02-12
CN101505753B (zh) 2014-05-21
MX2008015775A (es) 2009-04-17
US9676774B2 (en) 2017-06-13
JP2016094434A (ja) 2016-05-26
EP2354138A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
KR20090021215A (ko) 암의 치료를 위한 화합물 및 조성물
US9724338B2 (en) Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US8344007B2 (en) Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents
US10604510B2 (en) Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof
EP1931339B1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120611

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130930

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140827

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130930

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20141127

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140827

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101007382

Request date: 20141127

J301 Trial decision

Free format text: TRIAL NUMBER: 2014101007382; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141127

Effective date: 20160920

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160920

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20141127

Decision date: 20160920

Appeal identifier: 2014101007382

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2016201008612; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20160920

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016201008612

Request date: 20161121

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2016201008612; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161121

Effective date: 20161219

PJ1302 Judgment (patent court)

Patent event date: 20161220

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20161121

Decision date: 20161219

Appeal identifier: 2016201008612

Appeal kind category: Appeal against decision to decline refusal